Navigation Links
Cytopia Merger with Toronto-based YM BioSciences Inc.
Date:10/5/2009

and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter a Phase 1/II clinical study in 2009.

About YM

YM BioSciences Inc. is a life sciences product development company that identifies and advances a portfolio of promising cancer-related products at various stages of development. The Company is currently developing two late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM), and AeroLEF®, a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

About YM Programs

Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is significantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in more than 20 countries. In more than 5,000 patients reported as having been treated with nimotuzumab worldwide to date, no Grade IV incidents of radiation dermatitis have been described, severe rash has not been observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been rare. Nimotuzumab is licensed to YM's majority-owned subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology.

YM is developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using fentanyl because patients can individually control the analgesia required for their differing intensities o
'/>"/>

SOURCE Cytopia Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED DEVELOPMENT COMPANY
2. Cytopia Presentation on VDA CYT997 at AACR Conference
3. Cytopia Scientific Presentation on JAK2 Inhibitor Program at American Chemical Society Conference
4. Cytopia Letter to Progen Shareholders
5. Cytopia and Other Progen Shareholders Maintain Call for Meeting
6. Presentation on Cytopias JAK2 Inhibitor Program in Myeloproliferative Disorders
7. Cytopia Strengthens Scientific Team With US-Based Drug Development Specialist
8. Cytopia Presentation on JAK2 Inhibitor at American Association for Cancer Research
9. Sorrento Therapeutics, Inc. and QuikByte Software, Inc. Complete Merger
10. Schering-Plough Shareholders Approve Merger With Merck
11. TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger Transaction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... and BETHESDA, Md. , ... joining together with two institutes from the National Institutes ... tools for bringing safer, more effective treatments to patients ... National Center for Advancing Translational Sciences (NCATS) and the ...
(Date:1/14/2014)... January 14, 2014 In recent years, ... and methods in product development and promotion has led ... This mistrust, fueled by concerns about the insidious impact ... reports of spectacular fines to the world’s biggest pharmas ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), ... solutions for patients, physicians, the biopharmaceutical industry, regulators, ... the signing of a three-year Research Collaboration Agreement ... (FDA). This initiative is designed to generate ...
(Date:1/14/2014)... Washington, USA, and Cardiff, UK (PRWEB) January 13, 2014 ... photonics technology development leader with more than 20 years ... society for optics and photonics . Hainsey will serve ... are delighted to have Dr. Hainsey join SPIE as ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... ISELIN, N.J., Oct. 1 SyntheMed, Inc. (OTC,Bulletin ... development,and commercialization of anti-adhesion products and other surgical,implants, ... closing of a,private placement in which it received ... involved the issuance to investors of ten million ...
... Celsis Rapid Detection, a division of,Celsis International plc ... Sullivan,2008 North American Growth Strategy Leadership Award recipient ... and Release of,Pharmaceuticals., "The Celsis Rapid Detection ... pharmaceutical companies to significantly reduce,production cycle times in ...
... SoluLinK, Inc., a leader in,conjugation products and ... of its newest product, the One-Shot ChromaLink ... the components for the rapid,traceable biotinylation of ... sulfo-ChromaLink Biotin linker, a water-soluble, biotin labeling,reagent ...
Cached Biology Technology:SyntheMed Completes $4.0 Million Equity Placement 2Celsis Receives Frost & Sullivan 2008 Best Practices Award 2Celsis Receives Frost & Sullivan 2008 Best Practices Award 3SoluLinK Introduces New One-Shot ChromaLink(TM) Biotin Antibody Labeling Kit with Built-in Biotin Quantification. 2
(Date:4/23/2014)... NY. (Apr. 23 2014) A team ... stem cells (hNSCs) into the brains of nonhuman ... 22 and 24 months found that the hNSCs ... did not cause tumors. , The study will ... Cell Transplantation but is currently freely available ...
(Date:4/23/2014)... who have had a stroke, often suffer motor deficits ... study conducted in Taiwan, that will be published in ... is currently freely available on-line as an unedited early ... one group of stroke victims had their own peripheral ... and a similar group did not, those who received ...
(Date:4/23/2014)... TX (4/23/14) -- Researchers have found evidence of ... factors that increase aggressive behavior in children, especially ... not all children exposed to prenatal smoking will ... will not," said Brian Boutwell, Assistant Professor at ... and senior author on the study. "One ...
Breaking Biology News(10 mins):Study finds long-term survival of human neural stem cells transplanted into primate brain 2Autologous stem cell therapy improves motor function in chronic stroke victims 2Genetics risk, prenatal smoking may predict behavioral problems 2
... skin like a temporary tattoo, can alert marathoners, competitive bikers ... "hit the wall," scientists are reporting. The study, in ACS, ... of the sensor, which also could help soldiers and others ... monitor stamina and fitness. Joseph Wang and colleagues ...
... those painful lip blisters known as cold sores has an internal ... to literally blast its infectious DNA into human cells, scientists are ... the first in a human virus opens the door ... in the Journal of the American Chemical Society . ...
... MINNEAPOLIS/ST. PAUL (July 23, 2013) Mere months after ... the United States swine population, University of Minnesota researchers ... The first-of-its-kind test, which is available now, provides a ... U.S. PEDV strains. Characterized by acute diarrhea ...
Cached Biology News:U of M researchers unveil nation's first porcine virus rapid detection test 2
... The mycobacteria in ... cells to the injection site which enhances ... Freund's Adjuvant is used for the initial ... the subsequent boosts. Antigens (preferably in saline) ...
HiTrap Streptavidin HP, 5 x 1 ml. Category: Chromatography Systems & Accessories, Systems....
...
Request Info...
Biology Products: